Clinical Trials
28 trialsNCT07227415 2026-06-04
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT07011719 2026-06-02
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3 Recruiting
NCT07300241 2026-06-02
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Phase 1 Recruiting
NCT05536141 2026-06-01
ARC-20
Arcus Biosciences, Inc.
Phase 1 Recruiting
NCT05287945 2026-05-22
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Phase 1/2 Recruiting
NCT07244835 2026-05-13
A Study of DEG6498 in Participants With Solid Tumors
Degron Therapeutics Co.
Phase 1 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT07195682 2026-05-05
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07551349 2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2 Recruiting
NCT05865002 2026-04-17
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Aurigene Discovery Technologies Limited
Phase 1 Recruiting
NCT06026410 2026-04-14
FIT-001
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT07197580 2026-04-01
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT05433142 2026-03-05
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Xencor, Inc.
Phase 1 Recruiting
NCT05873686 2026-03-03
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Phase 1 Recruiting
NCT07072728 2026-03-03
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Psyence Australia Pty Ltd
Phase 2 Recruiting
NCT04485013 2026-02-18
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Tizona Therapeutics, Inc
Phase 1 Recruiting
NCT05366881 2026-01-20
CAMPERR
Adela, Inc
Recruiting
NCT06234605 2026-01-15
A Study of HC-7366 in Combination With Belzutifan (WELIREGā¢) in Patients With Renal Cell Carcinoma
HiberCell, Inc.
Phase 1 Recruiting
NCT07327489 2026-01-08
ELEPHAS-05
Elephas
Recruiting
NCT06962787 2025-11-17
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT03452774 2025-10-28
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Massive Bio, Inc.
Recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT05759923 2025-02-24
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients with Selected Advanced And/or Metastatic Solid Tumours
Molecure S.A.
Phase 1 Recruiting
NCT05961111 2023-07-27
A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Recruiting